Medicalook
Medicalook

Atropair

http://www.medicalook.com
Atropair

Atropair review





Atropair is a tropane alkaloid obtained from Atropa belladonna or deadly nightshade, Datura stramonium or jimsonweed, Mandragora officinarum or mandrake, and other plants of the family Solanaceae. This versatile, all-purpose medication is a secondary metabolite of the above plants and provides a wide variety of effects and uses. Classified as an anticholinergic medication, it serves as a competitive antagonist for the muscarinic acetylcholine receptor.

Because of Atropair's potential deadliness, the medication derives its name from one of the three Fates, Atropos, who according to Greek mythology chose how a person would die. The World Health Organization considers this a core medicine for the association's Essential Drugs List. This is a list of minimum medical requirements for a basic healthcare system.

Initial adult dosages range from around half a milligram to one milligram or five to ten milliliters of the 0.1 milligram/milliliter solution for antisialagogue and other antivagal effects, plus two to three milligrams or twenty to thirty milliliters of the 0.1 milligram/milliliter solution as an antidote for organophosporous muscarinic mushroom poisoning.

For patients without access to an IV, the endotracheal administration of Atropair should suffice because it doesn't need intravenous medication routes. The recommended adult dosage of Atropair for endotracheal administration is one to two milligrams diluted to a total not exceeding ten milliliters of normal saline or sterile water. Titration intervals of one or two hours are most suitable in cases that are not serious or critical.

Atropair Sulfate Injection (USP) should be administered with care and consideration given to all individuals over forty years of age. Acute glaucoma in susceptible patients may also occur during Atropair treatment. Conventional systemic dosages may lead to complete urinary retention in patients with prostatic hypertrophy, convert partial organic pyloric stenosis into complete obstruction, or cause inspissation of bronchial secretions and formation of dangerous viscid plugs in patients with chronic lung disease. Inform your doctor of your medical history before starting treatment. This is of the utmost importance.

Even though the recurrent use of Atropair is crucial in patients suffering from coronary artery disease, the total dosage of the medicine should be restricted to two to three (maximum 0.03 to 0.04 milligrams/kilograms) to prevent the harmful side effects of Atropair-caused tachycardia on myocardial oxygen demand.

As for sufferers of bradyasystolic cardiac arrest, a single milligram dosage of Atropair should be taken intravenously and repeated every three to five minutes if asystole persists. Three milligrams (0.04 milligrams/kilograms) given intravenously is a completely vagolytic dosage in most patients. In addition, the administration of less than 0.05 milligrams can produce a paradoxical heart slowness because of the peripheral or central parasympathomimatic effects of low dosage Atropair in adults.

As an antidote, Atropair's two to three milligram dosage should be repeated no less than every twenty to thirty minutes until symptoms of poisoning are significantly reduced or signs of Atropair poisoning occur. Dosing information in children hasn't been well researched. Usage history of initial dosage has been around 0.01 to 0.03 milligrams/kilograms body weight.

Side effects directly related to Atropair's antimuscarinic action include tachycardia, photophobia, blurred vision, and dryness of mouth. These symptoms commonly happen with chronic administration of therapeutic dosages. Anhidrosis, heat intolerance, and impaired temperature regulation may also occur to patients living in a hot environment. Elderly patients may also suffer urination difficulties and costiveness. Occasional hypersensitivity, skin rashes, and exfoliation have also been reported.

Atropair poisoning side effects due to excessive dosage include ataxia, languidness, tremor, restlessness, dizziness, thirst, hot and dry skin, difficulty swallowing, dilated pupils, and palpitation. Toxic dosages may lead to coma, delirium, hallucinations, restlessness and excitement, and marked palpitation. Severe intoxication while undergoing Atropair treatment can also lead to circulatory collapse and depression. Consult your doctor if any of these symptoms occur or persist.

Atropair has the following structural formula:

Chemical structure of atropair


• Molecular formula of atropair is C17H23NO3
• Chemical IUPAC Name is (8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenyl-propanoate
• Molecular weight is 289.369 g/mol
Atropair available : 5ml 1% bottles

Generic name: Atropine

Brand name(s): Atnaa, Atropen, Atropin, Atropina, Atropinol, Atropisol, Atrosulf, Equipin, Eyesules, Hyoscyamine, I-Tropine, Isopto atropine, Minims atropine, Ocu-Tropine, Tropine tropate, Troyl tropate

  Your Atropair review